Royal Bank Of Canada Has Lowered Expectations for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective lowered by analysts at Royal Bank Of Canada from $450.00 to $445.00 in a research report issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target would indicate a potential upside of 48.16% from the stock’s current price.

A number of other research firms have also weighed in on ALNY. Needham & Company LLC dropped their price objective on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. HC Wainwright reaffirmed a “buy” rating and issued a $510.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Morgan Stanley dropped their price objective on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research note on Friday, January 30th. Wall Street Zen lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, March 21st. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $472.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $471.96.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY traded down $9.14 during mid-day trading on Friday, hitting $300.36. 321,239 shares of the company traded hands, compared to its average volume of 1,308,125. The stock’s fifty day moving average price is $320.11 and its 200-day moving average price is $377.45. Alnylam Pharmaceuticals has a one year low of $245.96 and a one year high of $495.55. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. The firm has a market cap of $40.08 billion, a price-to-earnings ratio of 175.95 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $1.09. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the previous year, the company posted ($0.44) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 96.4% on a year-over-year basis. Research analysts anticipate that Alnylam Pharmaceuticals will post 6.75 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Pushkal Garg sold 1,775 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $319.74, for a total value of $567,538.50. Following the sale, the executive vice president directly owned 23,406 shares in the company, valued at approximately $7,483,834.44. The trade was a 7.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jeffrey V. Poulton sold 2,206 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $722,795.90. Following the sale, the executive vice president owned 64,273 shares in the company, valued at approximately $21,059,048.45. This trade represents a 3.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 38,656 shares of company stock valued at $12,370,696 in the last ninety days. Company insiders own 0.86% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ALNY. Groupama Asset Managment boosted its position in Alnylam Pharmaceuticals by 160.4% during the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after acquiring an additional 2,483,697 shares in the last quarter. Norges Bank bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $895,816,000. Arrowstreet Capital Limited Partnership boosted its position in Alnylam Pharmaceuticals by 698.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock valued at $618,158,000 after acquiring an additional 1,185,909 shares in the last quarter. Qube Research & Technologies Ltd bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at $369,943,000. Finally, AQR Capital Management LLC boosted its position in Alnylam Pharmaceuticals by 295.2% during the 3rd quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock valued at $336,009,000 after acquiring an additional 555,759 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q1 results significantly beat expectations: EPS $1.99 vs. consensus ~$0.90–1.43 and revenue $1.17B (up ~96% YoY), showing strong topline growth and margin improvement. Earnings Release
• Positive Sentiment: Multiple brokerages reiterate buy/positive views (consensus called a “Moderate Buy”); H.C. Wainwright remains a Buy, supporting analyst confidence in the franchise. Brokerage Consensus H.C. Wainwright
• Positive Sentiment: Wells Fargo nudged its price target slightly higher (to $377) while keeping an “equal weight” rating — a modest vote of confidence but not an outright upgrade. Wells Fargo PT Note
• Neutral Sentiment: FY‑2026 revenue guidance was set to a $5.3B–$5.8B range (consensus ~ $5.6B). The range includes the street number but its breadth may introduce caution around execution. Company Press Release / Slide Deck
• Neutral Sentiment: Detailed Q1 commentary and management remarks are available in the earnings call transcript and analyst write‑ups — useful for assessing product uptake and 2026 drivers but not news by themselves. Earnings Call Transcript Zacks Analysis
• Negative Sentiment: An outside review flagged that ALNY shares carry a “high risk of significant losses” under a Regulation category disclosure — a headline that can drive near‑term selling and increase perceived regulatory/operational risk. Outside Review Warning

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.